DNA vaccine encoding myristoylated membrane protein (MMP) of rock bream iridovirus (RBIV) induces protective immunity in rock bream (Oplegnathus fasciatus). Issue 6 (1st February 2018)

• Record Type: Journal Article
• Authors: Jung, Myung-Hwa; Nikapitiya, Chamilani; Jung, Sung-Ju
• Is Part Of: Vaccine. Volume 36:Issue 6(2018)
• Page Start: 802
• Page End: 810
• Publication Date: 2018-02-01
• Subjects: Rock bream -- Rock bream iridovirus -- Protection -- DNA vaccine -- Myristoylated membrane protein -- Major capsid protein -- Immune responses; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2017.12.077
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Injection of ORF008L (myristoylated membrane protein, MMP) vaccine offered high protection. TLR3, MyD88, Mx, ISG15, PKR, MHC class I, Fas, Fas ligand, caspase9 and 3 expressed high in vaccine group. The inflammatory cytokines (IL1β, IL8 and TNFα) were not enhanced in the ORF008L vaccinated group. Abstract: Rock bream iridovirus (RBIV) causes severe mass mortalities in rock bream ( Oplegnathus fasciatus ) in Korea. In this study, we investigated the potential of viral membrane protein to induce antiviral status protecting rock bream against RBIV infection. We found that fish administered with ORF008L (myristoylated membrane protein, MMP) vaccine exhibited significantly higher levels of survival compared to ORF007L (major capsid protein, MCP). Moreover, ORF008L-based DNA vaccinated fish showed significant protection at 4 and 8 weeks post vaccination (wpv) than non-vaccinated fish after infected with RBIV (6.7 × 10 5 ) at 23 °C, with relative percent survival (RPS) of 73.36% and 46.72%, respectively. All of the survivors from the first RBIV infection were strongly protected (100% RPS) from re-infected with RBIV (1.1 × 10 7 ) at 100 dpi. In addition, the MMP (ORF008L)-based DNA vaccine significantly induced the gene expression of TLR3 (14.2-fold), MyD88 (11.6-fold), Mx (84.7-fold), ISG15 (8.7-fold), PKR (25.6-fold), MHC class I (13.3-fold), Fas (6.7-fold), Fas ligand (6.7-fold), caspase9 (17.0-fold) and caspase3 (15.3-fold) at 7 days post vaccination in the muscle (vaccine injection site). Our results showed the induction of immune responses and suggest the possibility of developing preventive measures against RBIV using myristoylated membrane protein-based DNA vaccine.